SmartPharm’s gene-encoded therapeutics (GET) approach has multiple benefits compared to traditional viral-vectored gene therapy:
Minimally immunogenic; does not require immune suppression
Re-dosable in patients
Scalable, economic cGMP manufacturing
Reduced regulatory complexity
SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to rapidly develop a DNA-based neutralizing antibody that can be given to people as an intramuscular injection to block infection by COVID-19.
Other non-viral GET companies use either DNA or mRNA approaches. SmartPharm’s platform technology includes both technologies so we can address a broad range of therapeutic opportunities.
Selects type of nucleic acid based on specific therapeutic target and purpose
Protein sequence tuned for use with the specific nucleic acid platform and for the specific therapeutic application
- Protective treatment for SARS-CoV-2, the cause of coronavirus COVID-19
- Eliminating the need for recombinant enzyme replacement therapy in lysosomal storage diseases with a drug candidate in Gaucher disease type 1
- New treatments for tissue restoration and regeneration
Our Culture and Leadership
We have built a dynamic, smart organization around leaders with real-world experience in drug development and medical care